

# **Speakers**



Dr Carmen Boix Bernardini



Dr Steffen Groß



Dr Hiltrud Horn Horn Pharmaceutical Consulting



Dr Line Lundsberg-Nielsen Lundsberg Consulting



# ICH Q8 / ICH Q11 Training Course

From QbD to Process Validation



Live Online Training on 23/24 November 2021



Small & Biotec Molecules will be covered: Development, Process Validation, Lifecycle Approach (ICH Q12), Control Strategy / PAT / RTRT

# Highlights

- Quality by Design (QbD)
- Quality Target Product Profile (QTPP)
- Critical Quality Attributes (CQA)
- Critical Process Parameters (CPP)
- DoE Examples
- Design Space (DS)
- Control Strategy
- Process Analytical Technology (PAT)/RTRT
- ICH Q8 and ICH Q11
- ICH Q12: A Lifecycle Approach to Process Validation



Save money and book this live online training course in combination with the "ICH Q12 Training Course - How to use the PACMP in Practice" on 25 November 2021!

# **Objectives**

You will be updated on the latest regulatory developments and learn how to apply the respective paradigms in Pharmaceutical Development to be better able to design strategies for the implementation of Quality by Design (QbD) according to ICH Q8 and ICH Q11.

During this Live Online Training elements and methodologies associated with ICH Q8 and ICH Q11 will be discussed. All this will be illustrated with examples and case studies.

# Background

The impact of ICH Q8, Q9, Q10, and Q11 is changing both the regulatory expectations and the strategies of Pharmaceutical Development, and this impact will continue to grow, especially in view of the emerging ICH Q12 Guideline.

The QbD concept described in ICH Q8 and ICH Q11 have to be seen as an overarching paradigm and an interdisciplinary approach across the product lifecycle. It also systematically emphasises enhanced product and process understanding throughout the product lifecycle.

Ideally, application of ICH Q8 and ICH Q11 elements already starts in the early design phase of a drug product where both patient needs and process design are considered. The QbD concept requires a comprehensive understanding of the chemical and physical nature of the individual active substance(s) and excipients, and of the way their attributes interact in the formulation and how they bare impacted by the manufacturing process. During the design phase, it is important to establish the Quality Target Product Profile (QTPP), determine the Critical Quality Attributes (CQAs), identify Critical Process Parameters (CPPs) and Material Attributes (material CQAs) and to understand how the process parameters and material attributes affect the CQAs. The relationship between process inputs (material attributes and process parameters) and the CQAs is described in the Design Space and ensured during manufacturing with an enhanced control strategy, leading to improved process understanding, greater operational flexibility and opportunities for more efficient life cycle management activities.

ICH Q8 combined with the new Q12 will open the door to a powerful era of refined, modern and efficient pharmaceutical development and optimization for those companies who are ready to invest in this new paradigm.

# Target Audience

This Live Online Training is designed for all scientists, engineers, managers and executives from Pharmaceutical and Biotech Development units and support functions to Manufacturing, including Quality Assurance and Technical/CMC Regulatory Affairs, who are involved in the implementation of ICH Q8/Q11 elements.

# Programme Day 1



Provisional timetable, the actual schedule may vary depending on the situation

09.00 - 09.15 h Welcome and Introduction

09.15 - 10.15 h QbD for Drug Products: Background and Practical Aspects

- Essentials to know about QbD
- Steps for defining QTPP/CQA/CPP
- Benefits of the QbD Approach
- **Practical Examples**



10.15 - 11.00 h 🕇 🔼 QBD for Drug Products

QTPP - CQA - CPP for different kinds of formulations, e.g. Oral formulations (Tablets, vs. Biotech vs. Vaccines)

11.00 - 11.15 h Break

11.15 - 12.15 h QbD - Regulatory Perspective

- Current state of PAT & QbD implementation and regulatory challenges
- Quality by on-line (PAT) measurements
- Real time release testing: general considerations
- Going forward: ICH Q12 / Q13 / Q14



12.15 - 12.45 h Q&A Session 1

12.45 - 13.45 h Break

13.45 - 15.15 h DoE Examples for API Development

- DoE theory:
  - Resolution and confounding
  - Overview of available DoE designs
  - Basic statistics understanding my software analysis
  - Intuitive interpretation of the design: mapping
- Practical approach to DoE aimed to reduce the number of experiments:
  - Risk assessment: Fishbone (Ishikawa) diagram; FMEA (failure Mode Effect Analysis) and RPN analysis (Risk Priority Number)
  - Choosing the design
  - Practical tips for execution

15.15 - 15.30 h Break

15.30 - 16.30 h Development of the Drug Substance/ Drug Product (incl. Biotech)

- Strategies to consider for development
- Key points and potential pitfalls
- Ways to success for the submission of the dossier
- Typical questions from regulators



16.30 - 17.00 h Q&A Session 2

# Programme Day 2

09.00 - 10.00 h QbD for Drug Products

- Typical Points of Discussions within Teams
- Keypoints and potential pitfalls
- Ways to success for the submission of the dossier
- Typical questions from regulators

# 10.00 - 11.00 h How the QbD derived Control Strategy defines Process Validation

- QbD and PAT as an enabler for gaining Process Understanding and designing the process and the control strategy,
   PV stage 1 (establishing the control strategy)
- Different approaches to PV/PPQ depending on the type of control strategy, PV stage 2 (traditional, continuous process verification or hybrid approach used to verify the control strategy)
- Ongoing/Continued Process verification, PV stage 3 (verifying the validity and robustness of the control strategy)

11.00 - 11.15 h Break

11.15 - 12.15 h Process Validation - Case Study (Small Molecule Drug Product)
Case study related to the previous presentation (PV stage 1 and 2)

- Case example of a solid dosage form process enabled by a QbD approach
- Establishing the control strategy: Examples of the application of PAT/RTRT
- Validation of the process verification of the control strategy

12.15 - 13.00 h Ongoing Process Verification and Lifecycle Approach of a Process established from QbD Principles

- Continuous process verification versus continued/ongoing process verification (PV stage 3)
- Case study the continuation of the example from above (PV stage 3)
- ICH Q12, performance-based control and the link to PAT
- Life cycle management of the product, process and control strategy opportunities for a product developed using of a QbD principles



12.30 - 13.30 h Q&A Session 3

#### Participant's comment from the May 2018 course:

"Excellent speakers!"

Gordana Savi, Croatian Agency for Medicinal Products and Medical Devices

# Speakers



Dr Carmen Boix Bernardini, Almirall, Spain Carmen received her PhD in Organic Chemistry from the University of Valencia (Spain). After two years as Marie Curie post-doctoral Fellow (University of Not-

tingham), she joined the GSK Operations (UK) in 1999 as process chemist for new APIs, where she had her first contact with QbD. She has over 20 years of experience in development and optimization of chemical processes by QbD methodology. Currently, she is responsible for the industrialization of APIs in Ranke Quimica (Almirall chemical plant) in Barcelona.



Dr Steffen Groß, Paul-Ehrlich-Institut (PEI) Federal Institute for Vaccines and Biomedicines, Germany

Steffen Groß received his PhD degree from the Max Planck Research Unit Molecular Cell Biology Jena, Germany. Today, he is Head Section Monoclonal and Polyclonal Antibodies and Scientific Assessor (Quality, Pre-clinic) at the Paul-Ehrlich Institute (PEI).



Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Hiltrud is managing director of HORN Pharmaceutical Consulting with focus on CMC, GMP and Regula-

tory Affairs (EU and US). She started in pharma industry in 1990 and held several managerial positions within Hoffmann-La Roche and Knoll (now Abbott) with global responsibility within QC / QA / Regulatory Affairs / Project Management / Medical Writing. She was consultant for the biotech and life science industry at Cap Gemini Ernst & Young prior to starting her own business.



Dr Line Lundsberg-Nielsen Lundsberg Consulting Ltd., UK

Line is a scientist and runs her own consultancy business focusing on applying a science and risk ba-

sed approach for pharmaceutical development, process design, technology transfer, qualification and process validation. She has many years of experience within the pharmaceutical Industry and has a theoretical as well as practical approach to QbD, PAT and RTRT from working at Novo Nordisk and Lundbeck before being a consultant. Line is an active ISPE member and has had different chairing roles and is a well-recognized international speaker and instructor

#### GMP/GDP Certification Scheme

Building on your education the ECA GMP/GDP certification programmes provide you with the appropriate supplement to acquire this qualification. This training course is the first element for your additional certification. Simply choose any three courses within the programme according to your professional interest. Your certificate is then valid for two years. To renew it, you can pick any training from the ECA courses and conferences list within that two-years period allowing you to broaden your knowledge in GMP and GDP compliance. Please find more information at www.gmp-certification.org

Reservation Form (Please complete in full)

If the bill-to-address deviates from the

Online Training Courses ICH Q8 / ICH Q11 Training Course - From QbD to Process Validation, 23/24 November 2021 ICH Q12 - How to use the PACMP in Practice, 25 November 2021		Сотрапу	Purchase Order Number, if applicable	Country			take part, you have to inform us Privacy Policy: By registering for this event, I accept the processing of letaled according to the point of Personal Data. Concept Heidelberg will use my data for the processing of order, for which I hereby declare to agree that my personal data is store processed. Concept Heidelberg will only send me information in relation the antitiopate in the first privacy policy at http://www.gmp-compliance.org/gea_pt html). I note that I can ask for the modification, correction or deletion of my strangthing that processing or the processing of the processing
Live Online Training Courses □ ICH Q8 / ICH Q11 Training Course - From Q □ ICH Q12 - How to use the PACMP in Practic				ZIP Code			cancellation or non-appearance. If you cannot take part, you have to inform us soon as possible in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.  Incasey and on otappear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012).
Live Online T  Live Online T  LIVE ONLINE T	Title, first name, surname	Department	Important: Please indicate your company's VAT ID Number	City	Phone / Fax	E-Mail (Please fill in)	or speakers without notice or to cancel an event.  If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid, CONCEPT HEIDELBERGwill not be responsible for discount airfare penalities or other costs incurred due to a cancellation.  Terms of payment: Payable without deductions within 10 days after receipt of invoice.
specincations on the right, please fill out here:				CONCEPT HEIDELBERG P.O. Box 101764 Fax +49(0) 62 21/84 44 34	D-69007 Heidelberg GERMANY		General terms and conditions If you cannot attend the conference you have two options:  1. We are happy to welcome a substitute colleague at any time.  2. If you have to cancel entirely we must charge the following processing fees:  - Cancellation until 2 weeks prior to the conference 10 %,  - Cancellation until 1 week prior to the conference 50 %  - Cancellation within 1 week prior to the conference 100 %,  CONCEPT HEIDELBERG reserves the right to charge the materials, instructors,

order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties this order or similar ones. My personal data will not be disclosed to third parties also the privacy policy at http://www.gmp-compliance.org/eca\_privacy.html). I note that I can ask for the modification, correction or deletion of my data

#### Non-ECA Members € 1,790 EU GMP Inspectorates € 895 The conference fee is payable in advance after receipt of

Fees (per delegate, plus VAT)

ECA Members € 1,590 APIC Members € 1,690

invoice.

Would you like to save money? If you book the live online trainings "ICH Q8/ Q11 Training Course" and "ICH Q12 Training Course - How to use the PACMP in Practice'

(25 November 2021)" simultaneously the fee reduces as follows:

ECA Members € 2,290 APIC Members € 2,390 Non-ECA Members € 2,490 EU GMP Inspectorates € 1,440

#### Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.

#### Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

#### Conference language

The official conference language will be English.

#### Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG P.O.Box 10 17 64 69007 Heidelberg, Germany Phone +49(0)62 21/84 44-0 Fax +49(0)62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content please contact: Dr Andrea Kühn-Hebecker (Director Operations) at +49(0)62 21/84 44 35 or per e-mail at kuehn@concept-heidelberg.de

For questions regarding organisation please contact: Mr Rouwen Schopka (Organisation Manager) at +49(0)62 21/84 44 13, or per e-mail at schopka@concept-heidelberg.de.

Date of the Live Online Training

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At https://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast

Tuesday, 23 November 2021, 9.00 to 17.00 h CET Wednesday, 24 November 2021, 9.00 to 13.30 h CET

Technical Requirements

PE/0809021



# Speakers



Dr Joachim Ermer **Ermer Quality Consulting** 



Dr Steffen Groß PEI



Dr Ulrich Kissel Chair of the EQPA



Dr Lisa Matzen Boehringer Ingelheim



Luisa Paulo Hovione, Member of the ICH Q12 IWG



Dr Ramesh Raghavachari **FDA** 



# ICH Q12 Training Course

How to use the PACMP in Practice



Live Online Training on 25 November 2021



# Highlights

- How to implement ICH Q12 in practice
- Views and expectations of assessors (EU & US)
- Examples for Postapproval Change Management Protocols (PACMP) & Established Conditions (ECs)
- Analytical Lifecycle Management
- Strategies to use ICH Q12 effectively for global post-approval change management



Save money and book this live online training course in combination with the "ICH Q8 / ICH Q11 Training Course - From QbD to Process Validation" on 23/24 November 2021!

# Objectives & Background

The ICH Q12 topic was endorsed by the ICH Steering Committee in September 2014 and the draft ICH Q12 Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management was published for comment in December 2017. The final ICH Q12 Post-Approval Changes Guideline including two Annexes has been adopted in November 2019. The guideline aims to promote innovation and continual improvement, and strengthen quality assurance and reliable supply of product, including proactive planning of global supply chain adjustments.

The next phase will be the implementation of ICH Q12 across the ICH regions. However, especially in the EU, revision of local regulations (i.e. the EU Variations Regulation) will have to be performed to fully implement the concepts of Q12 (e.g.: the PACMP can currently be used in the US and in the EU, whereas the ECs are not yet used in the EU).

The new guideline has been developed to complement the existing ICH Q8 to Q11 guidelines, especially to enable full realization of more flexible regulatory approaches to post-approval CMC changes. The guideline applies to pharmaceutical drug substances and products (both chemical and biological). The guideline also applies to drug-device combination products that meet the definition of a pharmaceutical or biological product and to analytical methods.

In order to ensure a standardized approach, the guidance defines the categorization of Post-Approval CMC changes, Established Conditions (ECs), Post-Approval Change Management Protocols (PACMPs), and Product Lifecycle Management (PLCM) concepts. In particular, the guideline emphasizes the relationship between Regulatory Assessment and GMP Inspection.

Furthermore, the guideline describes how ECs are identified as well as what information can be designated as supportive information that would not require a regulatory submission, if changed. Guidance is also included for managing revisions of the ECs over a product's lifecycle.

Presentations, case studies and open discussions will help participants learn more about the lifecycle management of pharmaceutical products / analytical methods and provide a forum for discussing ICH's new guideline.

Participants will thus have the opportunity to give feedback and ask questions directly to ICH's Q12 Implementation Working Group (IWG) members on how to move forward with the transition to and implementation of the lifecycle approach.

The meeting will also address topics such as:

- What are "Established Conditions" for Manufacture and Control?
- How could Postapproval Change Management Protocols
- What is the impact of ICH Q12 on analytical method and process validation and transfer?
- What are the views and expectations of assessors and inspectors?

# Target Audience

The ECA wishes to actively involve QA personnel dealing with global change management, analytical chemists, QC analysts, R&D scientists, as well as manufacturing scientists (process developers) and managers, and regulatory affairs specialists and regulators.

# Programme



Provisional timetable, the actual schedule may vary depending on the situation.

09.00 - 09.15 Welcome and Introduction

09.15 - 10.00

PACMP - Postapproval Change Management Protocol

- What is a PACMP?
- Structure
- Examples

10.00 - 10.45

Views and Expectations of Assessors (EU)

- Current status
- Implementation in Europe
- Application of Q12 tools on post approval changes: Case Studies
- Lessons learned

10.45 - 11.00 Break

11.00 - 12.00

Change Implementation Control now and with ICH Q12

- How we control change implementation today
- How will ICH Q12 influence our future?
- Simplification or new complexity?
- OP considerations



12.00 – 12.30 h Q&A Session 1

12.30 - 13.30 Break

13.30 - 14.30

Analytical Lifecycle Management

- Overview on EFPIA/PhRMA Paper and the draft USP Chapter <1220>Alignment with manufacturing process
- Analytical Target Profile (ATP)
- Continuous improvement and regulatory flexibility
- ICH Q12, Q2(revision), Q14

14.30 - 15.15 Post-approval CMC Changes -How to Use ICH Q12 effectively

- Global Regulatory Complexity
- Agile post-approval change management within ICH Q12 including examples for
  - Classification of changes
  - Established Conditions / PACMPs / PLCM

15.15 - 15.30 Break

15.30 - 16.30 Drug Product Lifecycle and ICH Q12 -FDA Perspective

- Current status
- Implementation in US
- Application of Q12 tools on post approval changes:
  - PACMP
  - EC
- Lessons learned



16.30 – 17.00 h Q&A Session 2

#### Your Benefit

# Internationally Acknowledged Certificate from ECA Academy

The EU GMP Guide requires: "...
All personnel should be aware of
the principles of Good Manufacturing
Practice that affect them and receive
initial and continuing training,...".
This is why you receive an acknowledged
participant certificate, which lists the
contents of the Live Online Training in
detail and with which you document
your training.



#### This could be of interest for you as well

Why not online? GMP/GDP Training Courses/Conferences, Webinars and E-Learning

Take advantage of the wide range of "on demand" training opportunities offered by the ECA Academy. You can use various online offers at any time without software installation. There is an extensive selection of courses available. Simply book online - with a certificate of completion, of course.

Find out more at https://www.gmp-elearning.com and https://www.gmp-compliance.org/recordings

# Speakers



Dr Joachim Ermer, Ermer Quality Consulting, Germany Joachim has 30 years of experience in pharmaceutical analytics including global responsibilities as Director of Analytical Processes and Technology, Head

of Quality Control, and Head of QC Lifecycle Management (Sanofi, Frankfurt). Since December 2020, he works as a consultant for topics of pharmaceutical analytics and Quality Control. He is member of the USP Expert Committee "Measurement and Data Quality", and of the Ph. Eur. Chromatographic Separation Techniques Working Party.

Dr Steffen Groß, Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, Germany

Steffen Groß received his PhD degree from the Max Planck Research Unit Molecular Cell Biology Jena, Germany. Today, he is Head Section Monoclonal and Polyclonal Antibodies and Scientific Assessor (Quality, Pre-clinic) at the Paul-Ehrlich Institute (PEI).

9

Dr Ulrich Kissel, European QP Association, KisselPharma-Consulting, Germany Ulrich is Qualified Person and Chairman of the Board of Directors of the European Qualified Person Association (EQPA). He works as a GMP consultant and

contract QP to the Pharmaceutical Industry. Previous to his current role he held leadership positions in Quality and Supply Chain and served for many years as QP for Roche.



Dr Lisa Matzen, Boehringer Ingelheim, Germany

Lisa has held several positions within Boehringer including CMA RA Manager, Office Head CMC RA and Head of Cardiovascular Office (Global Regulatory Af-

fairs). Currently she is Head of the Global CMC RA Group, (Global Regulatory Affairs) at Boehringer.



Luisa Paulo, ICH Q12 IWG Member, Hovione, Portugal

Luisa is Compliance Director at Hovione and Chair of APIC's Quality Metrics Task Force. Currently she is member of the ICH Q12 Implementation Working

Group (IWG) representing APIC.



Dr Ramesh Raghavachari, FDA, USA Ramesh Raghavachari is currently the Chief of Branch I in the Division of Post-Marketing Assessment I under the Office of Lifecycle Products/ OPQ/

CDER. He has been with the FDA for over 18 years.

Reservation Form (Please complete in full)

fthe bill-to-address deviates from the specificaions on the right, please fill out here:

 $\Box$  ICH Q8 / ICH Q11 Training Course - From QbD to Process Validation, 23/24 November 2021 Ourchase Order Number, if applicable  $\square$  ICH Q12 - How to use the PACMP in Practice, 25 November 2021 Live Online Training Courses Important: Please indicate your company's VAT ID Number 'itle, first name, surname **Department** Phone / Fax City Fax +49 (0) 62 21/84 44 34 CONCEPT HEIDELBERG D-69007 Heidelberg P.O. Box 101764 GERMANY nal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca\_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

If you cannot take part, you have to inform us in will then be calculated according to the point of cellation or non-appearance. If you cann writing. The cancellation fee will then b time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receip to fipayment will not be confirmed)! (As of January 2012). German law shall apply. Court of jurisdiction is Heidelberg.

or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERGwill not be re-Terms of payment: Payable without deductions within 10 days after receipt of sponsible for discount airfare penalties or other costs incurred due to a cancelmportant: This is a binding registration and above fees are due in case of caninvoice.

E-Mail (Please fill in)

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.

2. If you have to cancel entirely we must charge the following processing fees: cannot attend the conference you have two options:

Cancellation within 1 week prior to the conference 100 %.
 CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

Cancellation until 2 weeks prior to the conference 10 %,
 Cancellation until 1 weeks prior to the conference 50 %

# Date of the Live Online Training Thursday, 25 November 2021, 9.00 to 17.00 h CET Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings. At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

#### Fees (per delegate, plus VAT)

ECA Members € 990 APIC Members € 1.040 Non-ECA Members € 1,090 EU GMP Inspectorates € 545

The conference fee is payable in advance after receipt of invoice.



#### Would you like to save money?

If you book the live online training courses "ICH Q12 Training Course - How to use the PACMP in Practice" and "ICH Q8 / ICH Q11 Training Course

- From QbD to Process Validation" on 23/24 November 2021 simultaneously the fee reduces as follows:

ECA Members € 2,290 APIC Members € 2,390 Non-ECA Members € 2,490 EU GMP Inspectorates € 1,440

#### Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

#### Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

#### Conference language

The official conference language will be English.

#### Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

**CONCEPT HEIDELBERG** P.O. Box 10 17 64 69007 Heidelberg, Germany Phone +49(0)62 21/84 44-0 Fax +49(0)62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.de

#### For questions regarding content please contact:

Dr Andrea Kühn-Hebecker (Operations Director) at +49(0)62 21/84 44 35, or at kuehn@concept-heidelberg.de.

#### For questions regarding organisation please contact:

Mr Rouwen Schopka (Organisation Manager) at +49(0)62 21/84 44 13, or at schopka@concept-heidelberg.de.